Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.56 |
| ▸ | TACR2 | P21452 | 12/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444326 | 0.99 | TRPV4 (0.57) | TRPV4TACR2CTSBCTSSCTSL | |
| SCHEMBL5441712 | 0.96 | TRPV4 (0.58) | TRPV4TACR2CTSBCTSSOPRM1 | |
| SCHEMBL5440108 | 0.93 | TRPV4 (0.55) | TRPV4TACR2CTSBCTSSCTSK | |
| SCHEMBL14361000 | 0.93 | TRPV4 (0.55) | TRPV4TACR2CTSBCTSSCTSK | |
| SCHEMBL5438091 | 0.90 | TRPV4 (0.46) | TRPV4TACR2CTSBCTSSCTSL | |
| SCHEMBL3917300 | 0.89 | TRPV4 (0.51) | TRPV4TACR2CTSBCTSSACKR3 | |
| SCHEMBL5434219 | 0.88 | CTSS (0.45) | TRPV4TACR2CTSBCTSSCTSL | |
| SCHEMBL4563567 | 0.88 | TRPV4 (0.53) | TRPV4TACR2CTSBCTSSCTSL | |
| SCHEMBL3917304 | 0.88 | TRPV4 (0.53) | TRPV4TACR2CTSBCTSSACKR3 | |
| SCHEMBL5432581 | 0.87 | CTSB (0.45) | TRPV4CTSBCTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885TACR2 82/4885CTSB 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.